iMDK
Chemical Name: 3-[2-[(4-Fluorophenyl)methyl]imidazo[2,1-b]thiazol-6-yl]-2H-1-benzopyran-2-one
Purity: ≥98%
Biological Activity
iMDK is a suppressor of endogenous midkine (MDK) expression. Inhibits PI 3-K signaling in H441 lung adenocarcinoma cells. Selectively attenuates growth of MDK-expressing cancer cells. Induces apoptosis in H441 cells and suppresses growth of H441 cell xenografts in mice.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
Inhibition of the growth factor MDK/Midkine by a novel small molecule compound to treat non-small cell lung cancer.
Hao et al.
PLoS ONE, 2013;8:e71093 -
Midkine Is a Potential Therapeutic Target of Tumorigenesis, Angiogenesis, and Metastasis in Non-Small Cell Lung Cancer
DH Shin, JY Jo, SH Kim, M Choi, C Han, BK Choi, SS Kim
Cancers (Basel), 2020;12(9):.
Product Datasheets
Citation for iMDK
The citations listed below are publications that use Tocris products. Selected citations for iMDK include:
1 Citation: Showing 1 - 1
-
Midkine is a dual regulator of wound epidermis development and inflammation during the initiation of limb regeneration.
Authors: Clara Et al.
Elife 2020;9
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for iMDK
There are currently no reviews for this product. Be the first to review iMDK and earn rewards!
Have you used iMDK?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
